Loading clinical trials...

Clinical Study of AFN50 Injection in the Autoimmune Diseases | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

Clinical Study of AFN50 Injection in the Autoimmune Diseases

NCT07408336•AlphaNa Bioscience Company Limited

Summary

This is an investigator-initiated trial designed to evaluate the safety, tolerability and primary efficacy of AFN50 injection for the treatment of autoimmune diseases.

Detailed Description

This study is a prospective exploratory clinical trial in subjects with autoimmune diseases, mainly relapsing and refractory systemic lupus erythematosus. The objective is to evaluate the safety, tolerability, and primary efficacy of AFN50 injection in relapsing and refractory systemic lupus erythematosus.

Eligibility

Age

18 - 69 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Be able to understand and voluntarily sign the written informed consent form;
•2. Patients aged between 18 and 69 (inclusive), of any gender, diagnosed with SLE according to the 2019 EULAR/ACR SLE diagnostic criteria;
•3. A history of SLE for at least 6 months, having used a stable standard treatment regimen for at least 8 weeks, with the dosage stable for 2 weeks, yet the disease remains active or has relapsed; Standard treatment refers to the stable use of the following drugs alone or in combination: non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids; immunosuppressants (including but not limited to cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine); targeted drugs (including but not limited to belimumab, telitacicept, eculizumab, rituximab);
•4. Oral corticosteroids are prednisone (or equivalent drug) ≥7.5mg/day and ≤30mg/day. If used in combination with immunosuppressants, there is no minimum daily dose requirement;
•5. Standardized treatment failure with hydroxychloroquine or at least two immunosuppressants;
•6. Screening period tests meet: positive blood antinuclear antibody (ANA), and/or positive anti-double-stranded DNA (anti-dsDNA) antibodies, and/or hypocomplementemia (low C3 and/or C4);
•7. Screening period SLEDAI-2K score ≥6 points. If scoring includes low complement and/or anti-ds-DNA antibodies, the score for SLEDAI-2K clinical symptoms (excluding low complement and/or anti-ds-DNA antibodies) should be ≥4 points;
•8. Appropriate bone marrow, coagulation, cardiopulmonary, liver, and kidney functions.
•Bone marrow function: Absolute Neutrophil Count (ANC) ≥1.5×10⁹/L (no granulocyte colony-stimulating factor (G-CSF) administered within 7 days prior to screening; a 14-day interval required for long-acting G-CSF); Hemoglobin (Hb) ≥80 g/L (no red blood cell transfusion within 14 days prior to screening; recombinant human erythropoietin is permitted. For patients meeting the Hb ≥80 g/L inclusion criterion, red blood cell transfusion is allowed during treatment to maintain hemoglobin level at ≥80 g/L); Platelet Count (PLT) ≥50×10⁹/L, Absolute Lymphocyte Count (ALC) ≥0.8×10⁹/L.
•Coagulation function: International Normalized Ratio (INR) or Activated Partial Thromboplastin Time (APTT) ≤1.5 times the upper limit of normal (ULN).
+6 more criteria

Exclusion Criteria

•1. Individuals with positive Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb), and Hepatitis B virus (HBV) DNA positivity or titers above the detection threshold; those with positive Hepatitis C virus (HCV) antibodies and HCV RNA positivity or titers above the detection threshold; individuals with Human Immunodeficiency Virus (HIV) antibodies positivity, CMV DNA positivity or above the detection limit; those with positive syphilis antigen or antibodies;
•2. Presence of other uncontrolled active infections;
•3. History of major organ transplantation (such as heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation;
•4. Receiving any mRNA-LNP product or other LNP medications within the past two years, and with a history of allergy to LNP and its components;
•5. History of live vaccine administration within the last 30 days;
•6. History of any of the following cardiovascular diseases within the last 6 months before screening: Class III or IV heart failure defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac diseases;
•7. Pregnant or breastfeeding women;
•8. Individuals with asthma, severe allergies;
•9. In the investigator's judgment, the participate is unlikely to complete all protocol-required study visits or procedures, including follow-up visits or adherence to the study participation requirements.
•10. Other conditions deemed inappropriate for participation in this clinical study by the investigator.

Locations (1)

First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Key Dates

Start Date

February 4, 2026

Primary Completion Date

February 4, 2028

Completion Date

February 3, 2029

Last Updated

March 5, 2026

Enrollment

ESTIMATED participants

Conditions

Autoimmune Diseases

Interventions

AFN50 injection

BIOLOGICAL

Contacts

Beicheng SUN, Dr

CONTACT

+86 551 6292 2800 sunbc0207@163.com

Huan ZHOU, Dr

CONTACT

+8613665527160 zhouhuanbest@vip.163.com

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT06948110

Autoimmune Diseases

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study of AFN50 Injection in the Autoimmune Diseases

Inclusion Criteria

Exclusion Criteria

Deciphering the Genetic Architecture of Autoimmune Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases